Roche and Exiqon Agree on Joint Marketing Approach for their RT PCR Assay Systems

PENZBERG, Germany--(BUSINESS WIRE)-- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Exiqon (NASDAQ OMX: EXQ) join marketing forces for Roche Applied Science´s RealTime ready assays and Exiqon`s miRCURY LNA™ Universal RT microRNA qPCR system. As indicated by respective links on their websites, each system will complement the cooperator ´s product portfolio. A bundle of measures like webinars and seminars and linked internet appearances are planned to promote the joint offer. Financial terms of the agreement were not disclosed.

Roche Applied Science´s RealTime ready assays offer maximized testing efficiency. Targets of choice are selectable out of gene lists of functionally related gene families or biological pathways. They can be ordered as single assays or configured as custom panel on a LightCycler® 480 Multiwell Plate. The function tested qPCR assays based on the proven Universal ProbeLibrary technology enable for optimum results, with detailed bioinformatics background information and novel error-detection features. The RealTime ready assays allow for discovery of the functionality of targets in complex biological pathways, to research their influence on processes leading to diseases or disorders.

Exiqon's miRCURY LNA™ Universal RT microRNA PCR system offers a combination of performance and ease-of-use on the microRNA real-time PCR market. The use of LNA™-enhanced PCR primers secures exceptional sensitivity and specificity enabling accurate quantification of very low amounts of microRNA obtained from difficult samples such as FFPE, serum/plasma and laser capture microscopy. The product line which includes reagents for the LightCycler® 480 System consists of microRNA Ready-to-Use PCR panels for expression profiling of human and rodent microRNAs, individual microRNA assays, reference genes and reagent kits.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers (Exiqon Pharma Services). Exiqon Diagnostics is developing a series of new molecular diagnostic products based on miRNA. Exiqon's goal is to gain a market-leading position for miRNA-based diagnostics. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information: www.exiqon.com.

For life science research only. Not for use in diagnostic procedures.
All trademarks used or mentioned in this release are protected by law.
LIGHTCYCLER and REALTIME READY are trademarks of Roche.
Exiqon, LNA, miRCURY, ProbeLibrary is a registered trademark of Exiqon A/S, Vedbaek, Denmark.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
or
Exiqon A/S
Lars Kongsbak, President and CEO,
Phone +45 4566 0888 (cell: +45 4090 2101)
Email: [email protected]

KEYWORDS:   Europe  Denmark  Germany  Switzerland

INDUSTRY KEYWORDS:   Stem Cells  Technology  Internet  Health  Genetics  Pharmaceutical  Research  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.